As the FLT3-ITD and NPM1 mutations are included, among other parameters, in the 2017 European LeukemiaNet (ELN) criteria7 of AML patients, we decided to check if telomere length and overall survival differ between patients in ELN risk groups (favourable, intermediate, adverse). This evidence concerns the gene FLT3 and acute myeloid leukemia.